Scality, a key player in data infrastructure software, has embarked on a strategic alliance with Biomemory, a company recognised for its industrial-grade DNA-based data storage solutions.
The collaboration aims to advance the development and enterprise-level integration of DNA-based cold archive storage solutions. This joint effort seeks to enhance existing storage infrastructure, encompassing flash, disk, and tape, by introducing DNA storage as a robust and secure long-term archival tier.
Enterprise-grade metrics
The partnership leverages Scality's software-defined S3 object storage platform, adept at optimising across diverse storage media, alongside Biomemory's DNA storage systems engineered for enterprise standards.
With an emphasis on modular design and enterprise-grade metrics, both companies plan to collaboratively chart an integration roadmap for introducing DNA storage as a secure cold archive option within environments managed by Scality’s ADI (Autonomous Data Infrastructure).
Archival storage solution
DNA data storage is evolving from scientific exploration to a viable commercial archival storage alternative
DNA data storage is evolving from scientific exploration to a viable commercial archival storage alternative, characterised by extended longevity and minimal maintenance.
It's particularly attractive for scenarios demanding exceptional data durability, such as national archives, genomic data repositories, and media and entertainment preservation. Moreover, it presents near-zero media refresh needs and zero resting power consumption, catering to organisations tasked with multi-decade data preservation where integrity is paramount.
Multi-decade timeframes
Biomemory's strategic acquisition of Catalog Technologies' assets enhances its market preparedness. This acquisition is a pivotal step in transitioning DNA Data Storage from research to an industrial-scale IT application. Jerome Lecat, CEO of Scality, remarks, "The future of data storage is not a single medium... Our partnership with Biomemory is a strategic investment in owning that future."
The partnership aligns with Scality's objectives to advance long-term data archiving capabilities, encompassing intelligent tiering and secure chain of custody with a focus on cyber-resilience. Scality intends to integrate the DNA storage into its CORE5 framework, thereby bolstering secure data storage practices. Erfan Arwani, CEO of Biomemory, comments on the synergy, stating, "Biomemory is building DNA storage with enterprise scale and enterprise expectations... Scality's hardware-aware, software-defined architecture is precisely the kind of control plane that DNA storage needs."
Scality, a global pioneer in data infrastructure software for AI-era storage at scale, announces a strategic partnership with Biomemory, the pioneer in industrial-grade DNA-based data storage systems, to accelerate the development and enterprise integration of DNA-based cold archive storage.
Together, the two companies will work to position DNA storage as a viable, ultra-secure, and long-term archival tier within modern object storage environments, complementing existing flash, disk and tape infrastructure rather than replacing it. To strengthen the partnership, Scality CEO Jerome Lecat is on Biomemory's board of directors.
Enterprise-grade metrics
The partnership brings together Scality's software-defined S3 object storage platform, built to span and optimise across multiple storage media types, with Biomemory's data centre-oriented DNA storage systems, which are designed with enterprise-grade metrics and a modular architecture.
The collaboration will focus on integrating DNA storage as a new, ultra-secure cold archive tier within Scality-managed storage environments including Scality ADI, its autonomous data infrastructure solution. The integration roadmap will be developed jointly by both companies in the coming months.
Archival storage solution
DNA data storage is transitioning from scientific research to commercial application, establishing itself as an archival storage solution optimised for extreme longevity and minimal operational demands. This emerging tier is uniquely suited for data that must endure for decades, offering near-zero media refresh requirements and zero power consumption at rest.
Its core value proposition is ideal for "keep forever, read rarely" scenarios where data integrity and extreme longevity are non-negotiable. Key applications include national archives, scientific and genomic data repositories, media and entertainment preservation, regulated financial and healthcare records, and sovereign or defense workloads. The most immediate demand is expected from organisations responsible for preserving high-value data over multi-decade timeframes, where loss, corruption or unreadability could carry severe financial, legal, operational or societal consequences.
Multi-decade timeframes
The recent acquisition of assets from DNA pioneer Catalog Technologies strengthens Biomemory's foundation and accelerates its market readiness. This strategic move marks a decisive step in Biomemory's journey to bring DNA Data Storage from the lab to an industrialised IT solution.
"The future of data storage is not a single medium; it is a spectrum of storage qualities, each optimised for the demands of the data it holds. DNA storage represents the logical culmination of that spectrum: a cold archive tier with density, secure immutability, and longevity that no conventional medium can approach. Our partnership with Biomemory is a strategic investment in owning that future. By bringing DNA into the Scality ecosystem now, we ensure our customers, which include the world's most demanding enterprises, governments, and service providers, will be ready to harness it as it matures. And by being on Biomemory's board, I'm personally committed to helping accelerate that journey for the entire industry." - Jerome Lecat, CEO, Scality.
Cyber-resilience framework
The strategic logic of the partnership is to extend existing capabilities in long-term data archive policy management, intelligent tiering, secure and cyber-resilient chain of custody. Scality is ideally positioned to serve as a massive-scale control plane around Biomemory’s DNA storage as the technology matures, enhancing the company’s CORE5 cyber-resilience framework to new levels of secure data storage.
"Biomemory is building DNA storage with enterprise scale and enterprise expectations. Not as a laboratory curiosity, but as a modular, data centre-ready archival system. To realise that vision, we work with software partners who understand the full stack: how data moves, how policies are enforced, how resilience is maintained across tiers, and how enterprises actually manage the lifecycle of their most valuable assets. Scality is the ideal partner for that challenge. Their hardware-aware, software-defined architecture is precisely the kind of control plane that DNA storage needs to reach its potential in production environments. Having Jerome on our board brings not just strategic alignment, but deep operational experience scaling storage platforms globally." - Erfan Arwani, CEO, Biomemory.
